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Background. The growth of patients ≥65 years on hemodial-
ysis is increasing. Guidelines recommend arteriovenous fistula
(AVF) access but their outcomes in elderly patients are contro-
versial. This study compared the outcomes of AVF in patients
<65 years old (65− group) versus those ≥65 years old (65+
group).
Methods. This retrospective analysis of prospectively col-
lected data included 444 incident, first-time AVF created in a
large dialysis center between January 1, 1995 and July 1, 2003.
The primary outcome of AVF cumulative patency was evalu-
ated using Kaplan-Meier survival analysis with log-rank test
comparison. A Cox model determined factors associated with
AVF loss.
Results. One hundred ninety-six patients (44%) were in the
65+ group. In total, there were 230 (52.2%) radiocephalic, 186
(42.2%) brachiocephalic, and 25 (5.6%) basilic vein transposed
AVF. The one-year AVF cumulative survival was 75.1% (65+
group) and 79.7% (65− group); the five-year survival was 64.7%
(65+ group) and 71.4% (65− group). The overall total proce-
dure, angioplasty, thrombolysis, and revision rates per access-
year were 0.83, 0.30, 0.66, and 0.16, respectively. The 65+ group
had a relative risk of 1.7 of their AVF failing to mature com-
pared with the 65− group. Multivariate analysis yielded these
variables significant for AVF loss: male sex HR 0.63 (95% CI
0.44–0.91), coronary artery disease HR 2.1 (95% CI 1.5–3.0),
and Caucasian ethnicity HR 0.63 (95% CI 0.44–0.91).
Conclusion. Age should not be a limiting factor when deter-
mining candidacy for AVF creation due to equivalent survival
and procedural rates. Failure of fistula maturation is a primary
concern to patients of all ages and demands further study.
Technology and innovation has successfully advanced
hemodialysis (HD) to its current state, reflected in part by
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a progressively broader acceptance of patients to this life-
sustaining therapy. Chronic HD became feasible for pa-
tients with end-stage renal disease (ESRD) when Schrib-
ner introduced the external arteriovenous shunt. This
great innovation in vascular access was advanced by Bres-
cia and Cimino, who developed the endogenous arteri-
ovenous fistula (AVF) [1]. To this day, the arteriovenous
fistula remains the HD vascular access of choice. It has
the lowest complication rate of all forms of access [2, 3],
requires the least intervention and cost to maintain [4],
and is associated with superior access and patient survival
[5, 6]. Worldwide, it is recommended as the first choice of
hemodialysis access [7, 8].
Despite the proven benefits of AVF, the prevalence
of use varies between and within countries [9]. Polyte-
trafluoroethylene (PTFE) grafts remain the predominant
(>50%) form of HD access in the United States [10].
Worldwide, initiation of dialysis with an AVF varies from
83% in Germany, 48% in the United Kingdom, and 15%
in the United States [11]. The prevalence of AVF use in
Canada is 51% [12]. Postulated reasons for this variation
include differences in practice and referral patterns that
impact on the ability to provide AVF in a timely manner,
reimbursement issues, and the changing demographics of
the dialysis population. When Cimino and Brescia origi-
nally described the AVF in 1966, the dialysis population
was a select group of young patients that excluded those
with diabetes. Today, in North America, the mean age of
dialysis initiation is 62 to 63 years old [12, 13], approxi-
mately 20 years older than the patients in which AVF were
first created. The population has changed so dramatically
that in some reports, the elderly population represents the
most rapidly growing population initiating dialysis [14].
In Canada, the absolute growth of patients ≥65 years
old on HD has grown by 400% over the past decade, or
20 times since 1981 [12, 15]. Also, in stark contrast to the
dialysis population in the 1960s, patients with diabetes
represent a substantial proportion of individuals treated
for ESRD, with incidences as high as 51% [14, 16]. In
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addition, these patients have significantly higher comor-
bidity than the nondiabetic patient [14]. These factors
have led nephrologists and surgeons to be wary of plac-
ing AVF in frail, elderly diabetic patients with potentially
tenuous vasculature. However, there are limited data on
the outcomes of AVF placement in the older dialysis pa-
tient, with conflicting results in the literature [17–20]. The
aim of our study was to compare the outcomes of arteri-
ovenous fistulas created at our dialysis center in patients
less than 65 years old (65− group) versus those 65 years
old or greater (65+ group).
METHODS
Study design
This study is a retrospective analysis of prospectively
collected data (for clinical care) on a cohort of patients
with consecutively created incident AVF within the Uni-
versity Health Network hemodialysis program. The pro-
gram manages between 350 and 400 HD patients and has
incorporated a multidisciplinary approach to access man-
agement since January 1996 [21]. The program is staffed
by a full-time vascular access coordinator, a part-time
nurse whose responsibilities include routine access flow
monitoring (ultrasound dilution technique), nephrolo-
gists, interventional radiologists, and vascular access sur-
geons.
All chronic HD patients who had an incident AVF cre-
ated within this program between January 1, 1995 and July
1, 2003 were included in the study. Prior to AVF creation,
all patients were assessed by the vascular access coordi-
nator and vascular surgeon; preoperative vein mapping
was not routinely performed. Among our vascular sur-
geons, there is not a standard approach to determining
which patient receives an AVF versus a graft. Despite this,
our program and our surgeons are unified in an aggres-
sive approach to AVF creation, with the ultimate decision
on access type left up to our surgeons’ individual discre-
tion. All AVF were tracked prospectively after creation,
regardless of whether it was the patient’s first or subse-
quent AVF. A strict policy was instituted that a minimum
maturation period of 6 to 8 weeks was required prior to
first venipuncture, and occurred after assessments by the
vascular access coordinator and the patient’s attending
nephrologist. Single-needle dialysis was then used for a
week before two needles were introduced at a low blood
flow rate, and gradually maximized at the dialysis nurse’s
discretion.
Access flow (Qa) monitoring using ultrasound dilution
(Transonic Systems, Ithaca, NY, USA) was introduced
to our unit in 1998 [22], resulting in bimonthly monitor-
ing of AVFs as per published guidelines [7, 8]. During
each monitoring session, a minimum of two flow mea-
surements was obtained in the first hour of dialysis, when
the patient was hemodynamically stable, with a systolic
blood pressure >110 mm Hg at a blood flow rate of 300
mL/min. An average of that session’s measurements was
documented. Low or declining flows (defined as <500
mL/min for AVF), or a drop of more than 20% compared
to the previous measurement triggered further investiga-
tion.
Since January 1, 1995, baseline demographic informa-
tion has been collected into a computerized database,
including patient characteristics: age, gender, ethnicity,
etiology of renal failure, and comorbidities. Coronary
artery disease (CAD) was defined if a patient had a my-
ocardial infarction, or required revascularization by an-
gioplasty, stenting, or bypass surgery. Peripheral vascular
disease (PVD) was defined by revasularization, amputa-
tion, and/or a history of claudication that also required
having ischemic extremity changes or gangrene. Diabetes
(DM) was defined if a patient required the current or
prior use of hypoglycemic agents or of insulin, or had the
diagnosis noted in their medical records at least twice by
two different physicians. Access characteristics collected
include: access type and anatomic location, dates of cre-
ation and loss, and reason for loss. The access coordinator
also prospectively tracked the Transonic measurements,
number of angiograms, angioplasties, surgical revisions,
and declottings of each AVF created. These specific inter-
ventions were integrated into the computerized database
from January 1, 1998 onward.
Definitions of outcomes
The primary outcome of our study was cumulative pa-
tency (also known as secondary patency or intervention-
assisted patency). We defined cumulative patency as the
time from AVF creation to the time of unsalvageable AVF
failure. Unless specified, all outcome rates reported in-
clude fistulas that failed to mature (FTM). Fistulas that
FTM were defined as those that met the following criteria:
(1) did not develop enough by six months after creation
to provide consistent dialysis for one month, and (2) this
failure persisted despite efforts to facilitate its matura-
tion (e.g., collateral vessel ligation) up to and including
six months after creation.
Secondary end points include the time to first interven-
tion (also known as primary patency, intervention-free, or
unassisted survival), and the rate of interventions in AVF
created in the older (≥65 years of age) versus younger
(<65 years of age) hemodialysis population. Interven-
tions include angioplasties, thrombolysis, and surgical re-
visions, but not angiograms. We also compared the effect
of gender and diabetes on AVF survival according to age
group, and determined factors related to AVF loss.
Due to the prospective nature of our clinical database,
the outcomes of our patients and their vascular accesses
were all known at the end of the study period or at the
time of censoring. Accesses were censored if the patient
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received a renal transplant, transferred to peritoneal dial-
ysis or another dialysis center, reached the end of the
study, or died with a functioning AVF. The minimum
follow-up time for this study was six months after AVF
creation. The study end date was February 15, 2004.
Statistical analysis
In the study period, patients may have received more
than one AVF; however, only their first access was ana-
lyzed, and only this data will be presented. We compared
baseline characteristics of these patients to patients ≥65
years old whom only used central venous catheters (i.e.,
no permanent access ever placed), and to those whose
first access was a PTFE graft. Continuous data were com-
pared using Student t test, while dichotomous data were
compared by chi-square analysis. Time-to-event distribu-
tions were estimated using the Kaplan-Meier method,
and compared using the log-rank test. A Cox model was
used to determine factors associated with AVF loss. The
proportional hazards assumption for covariates was eval-
uated using covariate-by-time interactions. All tests of
significance were two-sided with a P value <0.05. The
statistical software used was SAS (version 8.0) (SAS In-
stitute, Inc., Cary, NC, USA).
RESULTS
A total of 510 AVF was created within the study pe-
riod. Of these, 444 (87%) were first AVF, and only the re-
sults of the analysis of these 444 AVF will be reported for
the primary outcome of cumulative survival (secondary
or intervention-assisted patency). The patient and access
characteristics are presented in Table 1. In this study pop-
ulation, 196 patients (44%) were 65 years or older. Sixty-
five percent of all study patients were male, and 63%
were Caucasian. The median age of the 65+ group was
75 years, while that of the 65− group was 50 years. The
elderly were more likely to have a diagnosis of hyperten-
sion as the cause of their renal failure compared to those
under age 65, who were more likely to have a diagnosis
of glomerulonephritis (Table 1).
Patients ≥65 years old who had a graft created as their
first access within the same time period were more likely
to be female (59.4%; P < 0.0001), have diabetes as a co-
morbidity (59.4%; P < 0.0001), and as the cause of ESRD
(50.0%; P < 0.0001). Hypertension was less likely the
etiology of ESRD (14.1%; P < 0.0001). All other char-
acteristics were similar (data not shown). Also compared
with the 65+ group with AVF, elderly patients solely de-
pendent on central venous catheter dialysis access were
more likely to be Asian (12.5%; P = 0.02), have less hy-
pertension either as a comorbidity (69.7%; P = 0.009)
or as their etiology of ESRD (14.7%; P = 0.01), and to
have an “other” etiology of ESRD (38.5%; P = 0.003).
Table 1. Patient and fistula characteristics (N = 444)
Variable Age <65 Age ≥65
N 248 196
Mean age (SD) (range) 46 (12.0) (18–64) 74 (5.9) (65–90)
Sex (% male) 162 (65.3%) 136 (69.4%)
Ethnicityb
Caucasian 157 (63.3%) 135 (68.9%)
Black 28 (11.3%) 9 (4.6%)
Southeast Asian 18 (7.3%) 37 (18.9%)
South Asian 43 (17.3%) 14 (7.1%)
Other 2 (1.0%) 1 (0.5%)
Etiology
Diabetes 58 (23.4%) 43 (22.0%)
Hypertension 24 (9.7%) 64 (32.6%)
Glomerulonephritis 84 (33.9%) 37 (18.9%)
Interstitial nephritis 7 (2.8%) 4 (2.0%)
Othera 75 (30.2%) 48 (24.5%)
Comorbidities
DM 73 (29.4%) 58 (29.6%)
HTN 187 (75.4%) 162 (82.7%)
CAD 60 (24.2%) 86 (43.9%)
CHF 37 (14.9%) 56 (28.6%)
CVA/TIA 14 (5.7%) 26 (13.3%)
PVD 19 (7.7%) 19 (9.7%)
COPD 15 (6.1%) 15 (7.7%)
Anatomic site
Radiocephalic 139 (56.1%) 92 (46.9%)
Brachiocephalic 93 (37.5%) 93 (47.5%)
Brachiobasilic 14 (5.7%) 11 (5.6%)
Femoral 2 (<1%) 0
Those individuals less than 65 years old had less CAD (P < 0.0001), CHF
(P = 0.0004), and fewer CVA/TIAs (P = 0.005).
aIncludes those with PCKD, malignancy-related, unknown, “mixed” diagnosis
of HTN and DM, or other, such as unrecoverable ATN due to postsurgical
complications.
bCaucasian (white); Oriental: Southeast Asian (including patients of Chinese,
Japanese, Korean, and Indo-Chinese origins); South Asian (including patients of
East Indian, Pakastani, and Panjabi origins); black (including black patients from
Africa and Carribean); and others (Aboriginal, Arabic, Hispanic, Polynesian,
mixed, or unknown).
They were also more likely to have had a stroke/transient
ischemic attack (TIA) compared with patients with an
AVF (22.9%; P = 0.03). Other characteristics were simi-
lar (data not shown).
For the primary outcome, there were 61 failures, or 187
(75%) censored events in the 65− group, while in the 65+
group, there were 57 access failures, or 139 (71%) cen-
sored events. Reasons for censoring in the younger group
were as follows: 18% transfers (9 to home hemodialysis,
3 to peritoneal dialysis, and 22 to other dialysis centers),
10% (9) were transplanted, 15% (29) died, and 57% (104)
completed the study with a functioning access. In the 65+
group, 15% (21) were transferred to another dialysis cen-
ter, 2% (3) were transplanted, 40% (56) died with a func-
tioning access, and 43% (59) reached the end of the study.
There were 230 (52.2%) radiocephalic (RC), 186
(42.2%) brachiocephalic (BC), and 25 (5.6%) bra-
chiobasilic or basilic vein transposed (BVT) AVF created.
Younger patients were more likely to receive a radio-
cephlaic fistula (56% vs. 47%; P = 0.06), while older
patients were more likely to receive a brachiocephalic






































* Patients remaining in the study in the <65 and ≥65-year-
old groups




Fig. 1. Fistula survival comparison between 65− and 65+ groups.
Table 2. Cumulative patency
6 months 12 months 24 months 36 months Mean days
<65 ≥65 <65 ≥65 <65 ≥65 <65 ≥65 <65 ≥65
Overall 83.3 82.9 79.7 75.1 77.7 71.6 74.8 68.7 1950 1550
RCa 85.9 80.4 83.5 72.5 82.6 66.7 80.9 62.9 2089 1477
BC 81.1 86.6 77.5 79.4 73.2 77.2 64.8 72.9 801 1504
BB 76.9 67.5 68.4 54.0 NA NA NA NA 162 415
When fistulas that failed to mature were excluded, the cumulative patencies
for the 65+ group at 6, 12, 24, and 36 months were 91.0%, 86.1%, 83.3%, and
80.1%, respectively (mean was 1812 days).
aP value = 0.01.
fistula (47.5% vs. 37.5%; P = 0.03) (Table 1). At one year
after creation, the AVF cumulative survival was 75.1% in
the 65+ group and 79.7% in the 65− group (Fig. 1). At
five years, the cumulative survival was 64.7% in the 65+
group and 71.4% in the 65− group. The average AVF cu-
mulative survival in the 65+ group was 4.2 years versus
5.3 years in the 65− group (P = 0.28) (Table 2). Mean
values are represented in Table 2. The overall cumulative
patency did not differ between radiocephalic and brachio-
cephalic fistulas. However, when compared with radio-
cephalic AVF (median survival 1748 days), brachiobasilic
AVF (median survival 970 days) had significantly poorer
survival (P = 0.004). Brachiocephalic AVF (median sur-
vival 1333 days) was also superior to brachiobasilic AVF
(P = 0.008). Analysis by anatomic type between the age
groups showed better survival of radiocephalic AVF in
the 65− group (median survival 1979 days) compared
with the 65+ group (median survival 1616 days).
Three hundred and fifty-one accesses were evaluated
for secondary interventional-related outcomes. The inter-
vention required to maintain access patency and survival
was the same between age groups (Table 3). Transonic
measurements made when AVF were first used showed
average flow rates of 1224 mL/min in the 65− group ver-




group <65 ≥65 <65 ≥65 <65 ≥65
Overall 0.29 0.31 0.10 0.02 0.06 0.28
RC 0.30 0.30 0.09 0.02 0.03 0.61
BC 0.26 0.32 0.09 0.03 0.04 0.002a
BB 0.33 0.35 0.26 0.26 0.40 0.00

























Fig. 2. Intra-access fistula flow determined by ultrasound dilution.
Table 4. Primary patency of AVF
6 12 24 36 Median
months months months months days
<65 ≥65 <65 ≥65 <65 ≥65 <65 ≥65 <65 ≥65
Overall 80.5 86.1 65.1 64.8 50.7 48.9 37.8 43.8 747 645
RC 77.5 84.8 62.8 58.6 53.3 41.5 36.4 41.5 777 544
BC 87.1 88.7 69.9 70.8 49.6 57.1 40.6 45.4 683 1004
BB 61.5 66.7 49.2 33.3 36.9 NA NA NA 402 301
sus 1070 mL/min in the 65+ group (P value = 0.27). The
Transonic measurements made at baseline, immediately
before an intervention was required, and immediately af-
ter the intervention are shown in Figure 2. The average
change in flow prior to intervention was 29% in the 65−
group versus 24% for the 65+ group. The time to the
first intervention (Table 4) and the mean number of an-
gioplasties, thrombolysis, and surgical revisions (Table 3)
were not statistically different between age groups. The
overall rates of total procedures, angioplasty, thromboly-
sis, and revisions per access-year were and 0.52, 0.30, 0.07,
and 0.16, respectively.
The adequacy of dialysis provided by AVF in the 65+
and the 65− group were similar. The percent reduction of
urea (PRU) was 73.8% in the 65+ group and 71.6% in the
65− group (P = 0.06) after the first month that the AVF
was first needled. No difference between groups was ob-
served in subsequent measurements of dialysis adequacy
(data not shown).
Overall, 27% of the accesses were lost over the course
of the study (Table 5). Twenty-nine percent and 25%
of accesses failed in the over and under 65-year-old
groups, respectively. The primary reason for AVF loss was
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Table 5. Reasons for AVF loss
Reason for loss Age <65 Age ≥65 P value
Thrombosis/stenosis 34 (55.7%) 25 (43.9) 0.71
Failure to mature 21 (34.4%) 28 (49.%) 0.05
Radiocephalic 11 16 0.02
Brachiocephalic 8 9 0.80
Brachiobasilic 1 3 0.19
Other 1 0 N/A
Aneurysm/rupture 3 (4.9%) 1 (1.8%) 0.44
Ligation for severe steal
syndrome
1 (1.6%) 3 (5.2%) 0.21
Ligation due to severe
high cardiac output
2 (3.3%) 0 (0.0%) 0.21
Total losses 61 57
N/A, not available.
thrombosis (59/118; 50%) that occurred independently of
age. However, of the 27% of AVF lost, 42% (49/118) was
lost due to failure of maturation; 49% (28/57) of AVF
lost in the 65+ group FTM compared with 34% in the
65− group (P value = 0.05). The relative risk of FTM in
the elderly patient with AVF compared with a younger
patient is 1.7. There was no other statistically significant
cause of AVF failure between the two groups (Table 5).
Of those that failed to mature, 43% (21/49) had an at-
tempted intervention, and of these interventions, a third
(7/21) was not amenable to intervention. The remainder
of the fistulas that FTM were either followed-up and as-
sessed in vascular access clinic without subsequent in-
tervention (24%), patients refused further intervention
(6%), and no apparent vascular clinic follow-up or in-
tervention (18%). There were more patients ≥65 years
(11/29) who were followed-up without subsequent inter-
vention than younger patients (1/21).
Overall, cumulative survival did not differ by age but
did differ by gender (P = 0.01), diabetes status (P = 0.01),
presence of CAD (P = 0.0005), history of heart failure
(P = 0.03), and ethnicity (Caucasian vs. non-Caucasian)
(P = 0.006) when evaluated by univariate analysis. Specif-
ically, in the 65− group, women (P = 0.0013) or patients
with heart failure (P = 0.006) had poorer access survival
compared to men or patients without heart failure, re-
spectively. However, gender and heart failure did not im-
pact AVF survival in the 65+ group. In both age groups,
having CAD was associated with poorer AVF survival
(age 65− group, P = 0.008; age 65+ group, P = 0.02),
while being Caucasian showed a trend toward improved
AVF survival (age 65− group, P = 0.08; age 65+ group,
P = 0.06). This AVF survival advantage was also seen in
the nondiabetic patients younger than 65 years old com-
pared with diabetic patients (P = 0.05), but diabetes sta-
tus did not affect AVF survival in the 65+ group.
On multivariate analysis, the following variables and
hazard ratios where significant for access failure: male
sex HR 0.63 (95% CI 0.44–0.91), CAD HR 2.1 (95%
CI 1.5–3.0), and Caucasian HR 0.63 (95% CI 0.44–0.91).
Because we were able to determine the outcome of all of
our patients’ AVF at the time of censoring or study end,
we were able to perform a sensitivity analysis using logis-
tic regression that resulted in the same three significant
variables.
DISCUSSION
Our study is among the first to demonstrate viability in
promoting the creation of AVF in elderly hemodialysis
patients. These data show equivalent fistula survival and
intervention rates compared to those of younger age. Our
findings support published guideline recommendations
that promote AVF as the permanent HD access of choice,
regardless of age.
The literature is rich with studies that have included
age as a covariate in analysis of access survival and var-
ious outcomes, but yield conflicting results and conclu-
sions. Although that literature is abundant, there have
been few studies that specifically evaluate the association
of older age and AVF outcomes. An early study, pub-
lished in a letter, indicated that >95% of elderly patients
with an AVF were still using their fistula three months
after initiating dialysis [19], but did not report longer
follow-up. Hinsdale at el [23] were able to attempt AVF
in 3/56 patients >65 years old (all were diabetic), all of
which thrombosed. Lin et al [24] prospectively studied
176 newly created AVF, and found that age itself did not
predispose to poor outcomes, but that the combination
of age and diabetes increased the risk of access failure.
Staramos et al [25] described their vascular access expe-
rience in patients >70 years old. Their AVF and grafts
had similar “primary cumulative patency” rates; the au-
thors conclude that graft survival was superior to AVF in
this population based on improved “secondary cumula-
tive patency” rates. However, the secondary procedure
in AVF studied was to have a new AVF created, ending
the survival time of the original AVF, while survival time
continued to accumulate in grafts that underwent correc-
tive interventional procedures. Their conclusions conflict
with a large retrospective descriptive study over a mean
of 15 years of 494 permanent accesses in complex, elderly
dialysis patients who had prior access failures [20]. These
authors concluded that the best results were obtained in
elbow AVF.
Our study evaluated the association of age on AVF
outcomes using a large, detailed dataset, which provided
information on access specific survival (e.g., radiocephalic
vs. brachiocephalic AVF), intra-access flows, intervention
rates, and etiology of AVF losses. The clinical data ob-
tained allowed adjustment of patient level comorbidity
when determining predictors of access loss. The comor-
bidity observed in our patients largely reflects that of
the North American hemodialysis population. These data
may provide a mirror to what dialysis programs might
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expect when promoting AVF creation in an environment
where selection criteria and practice patterns among sur-
geons may vary.
The cumulative patency rate (Table 2) observed in our
study is comparable to the literature [26–28]. For exam-
ple, Golledge et al [29] had cumulative patency rates (af-
ter angioplasty, thrombolysis, or surgical intervention) of
70% at one year and 63% at two years. In our study, the
average one- and two-year cumulative patencies for ra-
diocephalic fistulas were 72.5% and 66.7%, respectively,
and were consistent with average radiocepahlic AVF pa-
tencies of 67.3% and 56.6%, obtained from a number of
studies that excluded AVF that failed to mature [30]. Our
study is also consistent with a study by Konner et al of 748
AVF that demonstrated excellent AVF survival in elderly
diabetic patients (80% at 2 years). While the majority of
AVF created in their study were in the upper arm, we are
able to extend their findings and emphasize that excel-
lent cumulative survival rates can be achieved in smaller,
radiocephalic vessels as >50% of AVF in our study were
radiocephalic.
Our data support the K-DOQI guideline recommenda-
tions for using radiocephalic vessels first, if possible, be-
fore proceeding to upper arm AVF placement. There was
no difference in survival between radiocephalic and bra-
chiocephalic AVF, but both were superior to BVT. Our
data contrast other studies, such as Miller et al’s, which
demonstrated an overall adequacy rate of almost twice
as high for upper arm AVF compared with lower arm
AVF; the difference was fourfold in patients who were 65
years old or more (56% vs. 12%). This was also marked
in female and in diabetic patients. However, the dialy-
sis population studied differed in that 82% were black
compared with fewer than 15% in our study population.
Dixon et al [31] also demonstrated improved one-, three-,
and five-year upper arm AVF cumulative patency rates of
71%, 57%, and 57% compared with lower arm AVF rates
of 54%, 46%, and 36%. Interestingly, the majority of pa-
tients (>90%) were white. Our experience with BVT is
still early, and prospective future study is underway.
The time to first intervention or primary patency in
our study was 65% at one year. This is consistent with the
one-year primary patency of 67% in 68 AVF of elderly
patients previously reported [25], and with a study of 107
radiocephalic AVF (average patient age of 63 years) that
showed primary patencies of 69% at one year and 56%
at two years [29]. When interventions were required in
our patients, no differences in rate were found between
the 65+ group compared with the 65− group. In addi-
tion to using standard reporting of our data by survival
analysis (time to first intervention) [32], we also reported
the rate of intervention (average number of events per
access year) (Table 3). This has particular practical rel-
evance to patients who participate in decision making
of their permanent access, and who want to know what
to expect once their AVF is placed. Astor et al reported
0.39 procedures/access-year, but this rate does not include
angioplasties, which comprise a majority of the interven-
tions [33]. Dixon et al reported a total procedure rate
of 1.44 per year for upper arm fistulas. This rate may be
higher than ours since approximately a third of accesses
were secondary accesses, and may bias toward greater
susceptibility to intervention due to preexisting condi-
tions that may have led the first access to fail. Oliver et al
also reported similar angioplasty and thrombolysis rates
in a study of 115 upper arm AVF [34]. Our average sur-
gical revision rates were similar to Konner’s study of 748
AVF with a rate of 0.18 revisions per patient-year [17].
In our analysis, we included fistulas that FTM. Signifi-
cant improved differences in AVF outcomes and paten-
cies can be noted (see Table 2), and have been previously
demonstrated when AVF that failed to mature were ex-
cluded in study analysis [26, 34]. Therefore, given the in-
clusion of AVF that FTM in our analysis, and its similarity
to data from the literature where FTM was excluded, our
data demonstrate that high cumulative patencies can be
achieved in the elderly population.
Including AVF that failed to mature in our analyses also
highlighted its importance. Our finding of a difference in
FTM as an etiology of loss in the 65+ group (49%) versus
65− group (34%) has also been demonstrated by Miller
et al. They observed FTM of AVF in 53.5% of patients
>65 years old versus 30.0% in those <65 years old. Rates
as high as 70% have been reported [35], although other
studies report values between 11% and 27% [1, 28, 36].
Despite its importance, few studies have identified pre-
dictive risk factors for the failure of fistula maturation
[36–38]. Miller et al identified poorer fistula adequacy in
patients who were older, female, or diabetic [37]. In con-
trast, gender and diabetes status were not found signifi-
cant in a multivariate analysis by Patel et al [38]. Indeed,
factors influencing fistula maturation require more at-
tention. Aside from surgical influence (skill, experience,
preference), risk factors such as gender, age, ethnicity,
comorbidity, vessel size, and quality are potentially im-
portant. Furthermore, once FTM is identified, aggressive
measures to correction, irrespective of age, should be pur-
sued. In this study, interventions were withheld in (older)
patients struggling with competing serious illnesses that
required priority attention. Also, surgeons tended to hes-
itate when patients were stable but were frail and had
multiple comorbidities in the presence of a functioning
central venous catheter. Ongoing multidisciplinary edu-
cation of the longer-term pros and cons, and optimization
of each access type, is necessary to maximize vascular ac-
cess care.
In our multivariate analysis, we found that being non-
Caucasian, female, and having CAD are important pre-
dictors of AVF loss. There are multiple studies that have
found a variety of different risk factors for access loss.
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Aside from statistical power, limitations relating to data
collection, and varying definitions, nonagreement among
studies may relate to differing etiologies for access loss
that are not examined separately. The two primary rea-
sons for AVF loss are thrombosis and FTM, which have
somewhat different, but sometimes related, underlying
pathophysiologies. For example, it is well recognized that
thrombosis is related to stenosis, while in order for a fis-
tula to dilate and mature, it requires adequate inflow and
outflow. This, in turn, rests on the overall integrity of the
arterial and venous vessels, and the absence of collateral
development. Recognizing this limitation in our study,
our group is currently evaluating risk factors that may be
predictive specifically of failure of fistula maturation.
Also to be considered in our study is its description of
a single-center experience, which may limit its external
generalizability. There is also the potential presence of
selection bias. It is possible that elderly patients in this
study who received AVF are not representative of the
overall elderly population starting dialysis. We have pre-
sented data on patients’ characteristics who use only cen-
tral venous catheters, and those who had a graft created
as their first permanent access for comparison.
CONCLUSION
Age should not be a limiting factor when choosing AVF
as the optimal permanent HD access. Radiocephalic and
brachiocephalic AVF survival, and use of interventions
were similar among old and young dialysis patients. How-
ever, patients ≥65 years old have an increased risk of
their fistulas failing to mature (RR 1.7; P = 0.05), despite
greater use of upper arm AVF. Fistulas that fail to mature
present as a primary concern to patients of all ages, and
demand further study.
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